UK has gone from a leader to a laggard in biopharma, Eli Lilly CEO says

1. Dave Ricks discusses halted investments in the U.K. due to pricing concerns. 2. Eli Lilly paused plans for a U.K. biotech incubator amid unfavorable policies. 3. The U.K. is perceived as unattractive for biopharma investments, affecting LLY's strategy. 4. Regulatory changes needed for a healthier investment climate in the U.K. 5. Lilly's price hike for Mounjaro in the U.K. reflects ongoing market challenges.